Thrombocytosis and hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 58, Issue 6, 2013, Pages 1790-1796

  Carr, Brian I ^a   Guerra, Vito ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

HCC; Portal vein thrombosis; Size; Thrombocytosis

Indexed keywords

BILIRUBIN;

ALCOHOL CONSUMPTION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOCYTOSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84879507887     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2527-3     Document Type: Article

References (48)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Establishment of world-wide burden of cancer in 2008: GLOBCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58:273-277.
3. Beasely RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,000 men in Taiwan. Lancet. 1981;22:1129-1133.
4. Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31:71-82.
5. Yu SZ, Chen G. Blue-green algae toxins and liver cancer. China J Cancer Res. 1994;6:9-17.
6. Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water and hepatoma. Quantitative evaluation using GGT method. Zhonghua Yu Fang Yi Xue Za Zhi. 1990;234:203-205.
7. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:405-440.
8. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348-1355.
9. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212-2222.
10. Kumada T, Toyoda H, Kiriyama S, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010;82:539-545.
11. Lok AS, Seeff LB, Morgan TR, HALT-C Trial Group, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148.
12. Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology. 2012;83:339-345.
13. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012;83:331-338.
14. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinic-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105:65-75.
15. Okuda K, Nakashima T, Kojiro M, et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology. 1989;97:140-146.
16. Trevisani F, D'Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer. 1995;75:2220-2232.
17. Truant S, Boleslawsky E, Duhamel A, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012. Epub. 08/03/2012.
18. Trousseau A, Bazine V, Cormack J. Lectures on Clinical Medicine. USA: R. Hardwicke; 1867.
19. Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wissensch Med. 1872;39:237-249.
20. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Int Med. 1964;114:497-500.
21. Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:2472-2477.
22. Chen CC, Chang JY, Liu KJ, et al. Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Ann Oncol. 2005;16:988-989.
23. Nickerson HJ, Silberman TL, McDonald TP. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer. 1980;45:315-317.
24. Hsiao CC, Chuang JH, Tiao MM, et al. Patterns of hepatoblastoma and hepatocellular carcinoma in children after universal hepatitis B vaccination in Taiwan: a report from a single institution in southern Taiwan. J Pediatr Hematol Oncol. 2009;31:91-96.
25. Kuo CY, Liu HC, Chang MH, et al. Hepatoblastoma in infancy and childhood: a clinical and pathological study of 32 cases. Zhonghua Min Guo Xiao. 1991;32:79-87.
26. Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells. 1998;16:329-333.
27. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610-618.
28. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576-590.
29. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interactions in solid tumors. Int J Cancer. 2012;130:2747-2760.
30. Cho MS, Bottsford-Miller J, Vasquez HG, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012. Epub. 09/10/2012.
31. Peterson JE, Zurakowski D, Italiano JE Jr, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265-273.
32. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001;13:791-801.
33. Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond). 2000;99:207-214.
34. Nalesnik MA, Michalopoulos GK. Growth factor pathways in development and progression of hepatocellular carcinoma. Front Biosci (School Educ). 2012;4:1487-1515.
35. Yang ZF, Ho DW, Lau CK, et al. Platelet activation during tumor development, the potential role of BDNF-TrkB autocrine loop. Biochem Biophys Res Commun. 2006;346:981-985.
36. Zhou J, Tang YZ, Fan J, et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol. 2000;126:57-61.
37. Gotzmann J, Fischer AN, Zoler M, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene. 2006;25:3170-3185.
38. Stock P, Monga D, Tan X, et al. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther. 2007;6:1932-1941.
39. Maass T, Thieringer FR, Mann A, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011;128:1259-1268.
40. Okada H, Honda M, Campbell JS, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res. 2012. Epub. 05/31/2012.
41. Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA. 2005;102:3389-3394.
42. Soll C, Jang JH, Riener MD, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51:1244-1254.
43. Lesurtel M, Clavien P-A. Serotonin: a key molecule in acute and chronic liver injury. Clin Res Hepatol Gastroenterol. 2012. Epub. 06/29/2012.
44. Gauglhofer C, Sagmeister S, Schrottmaier W, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53:854-864.
45. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2001;12:56.
46. French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7:e36713.
47. Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165-E2172. Epub. 07/02/2012.
48. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arter Thromb Vasc Biol. 2010;30:2362-2367.